natgillin/translations-raw huggingface dataset:
In all three studies, patients taking Rienso had higher average increases in haemoglobin: 1.2 g/dl versus 0.5 g/dl; 0.8 g/dl versus 0.2 g/dl; and 1.0 g/dl versus 0.5 g/dl.
V vseh treh študijah so imeli bolniki, ki so jemali zdravilo Rienso, višji povprečni dvig ravni hemoglobina: 1,2 g/dl v primerjavi z 0,5 g/dl; 0,8 g/dl v primerjavi z 0,2 g/dl in 1,0 g/dl v primerjavi z 0,5 g/dl.
In all three studies, the co-primary endpoints were the proportion of patients who achieved a PASI 75 response and an sPGA of 0 (“clear”) or 1 (“minimal”) response at Week 12 versus placebo.
V vseh treh študijah so bili sočasni primarni opazovani dogodki deleži bolnikov, ki so dosegli odziv PASI 75 in odziv sPGA 0 ("čisto") ali 1 ("minimalno") v 12. tednu v primerjavi s placebom.
In all three studies, the main measure of effectiveness was the number of patients who had responded to treatment after a year, measured using a standard eye test chart.
Glavno merilo učinkovitosti v vseh treh študijah je bilo število bolnikov, ki so se po enem letu zdravljenja odzvali nanj, pri čemer je bil uporabljen standardni očesni test.
In all three studies, the main measure of effectiveness was the number of patients who had responded to treatment after six weeks.
V vseh treh študijah je bilo glavno merilo učinkovitosti število bolnic, ki so se po šestih tednih odzvale na zdravljenje.
In all three studies, the main measure of effectiveness was the number of patients who had very low levels of HIV in their blood (viral load).
V vseh treh študijah je bilo glavno merilo učinkovitosti število bolnikov, ki so imeli zelo nizke ravni HIV v krvi (virusno breme).
In all three studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 12 weeks after the end of treatment.
Glavno merilo učinkovitosti je bilo v vseh treh študijah število bolnikov, pri katerih krvne preiskave 12 tednov po koncu zdravljenja niso pokazale prisotnosti virusa hepatitisa C.
In all three studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 12 weeks after the end of treatment.
Glavno merilo učinkovitosti v vseh treh študijah je bilo število bolnikov, pri katerih krvne preiskave 12 tednov po koncu zdravljenja niso pokazale prisotnosti virusa hepatitisa C. Skupna analiza rezultatov študij je pokazala, da so bili pri
In all three studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus six months after the end of treatment.
V vseh treh študijah je bilo glavno merilo učinkovitosti število bolnikov, pri katerih krvne preiskave šest mesecev po koncu zdravljenja niso pokazale znakov virusa hepatitisa C.
In all three studies, the main measure of effectiveness was the number of patients with an improvement in symptoms of at least 20% after six months.
V vseh treh študijah je bilo glavno merilo učinkovitosti število bolnikov z najmanj 20-odstotnim izboljšanjem simptomov po šestih mesecih.
In all three studies, the main measure of effectiveness was the ‘protective effectiveness’ of the vaccine, calculated by comparing the number of people in the studies who developed cholera after receiving Dukoral and after receiving placebo.
Glavno merilo učinkovitosti v vseh treh študijah je bila učinkovitost zaščite, ki jo je nudilo cepivo, izračunana na podlagi primerjave števila udeležencev, pri katerih se je po cepljenju s cepivom Dukoral pojavila kolera, s številom tistih, ki so za kolero zboleli po prejemanju placeba.
In all three studies, the patients also took two reverse transcriptase inhibitors (another type of antiviral medicine).
V vseh treh študijah so bolniki jemali tudi dva zaviralca reverzne transkriptaze (drugi vrsti protivirusnega zdravila).
In all trials, the main measure of effectiveness was the presence of antibodies against the virus and infectious FeLV in the vaccinated kittens’ blood.
V vseh preizkušanjih je bilo glavno merilo učinkovitosti prisotnost protiteles proti virusu in kužnemu virusu FeLV v krvi cepljenih muck.
In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman’s body weight or BMI.
Pri vseh ženskah je treba nujno kontracepcijo vzeti čim prej po nezaščitenem spolnem odnosu, ne glede na telesno maso ali ITM ženske.
In almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4).
V skoraj vseh primerih, ko je bilo odmerjanje prekinjeno zaradi zvišanih transaminaz, pozneje pa se je spet začelo, se je lahko odmerjanje ivakaftorja uspešno spet začelo (glejte poglavje 4.4).
in ALT elevations and therefore, early discontinuation of
+ dasabuvir je povzročila zvišanje ALT in zaradi tega
in ALT elevations and therefore, early discontinuation of
povzročila zvišanje ALT in zaradi tega zgodnje prenehanje
In AMD, Lucentis was more effective at preventing a worsening of vision than its comparators.
Zdravilo Lucentis je bilo pri preprečevanju poslabšanja vida pri starostni degeneraciji makule učinkovitejše od primerjalnih zdravil.
In an 18 month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.
V 18-mesečni študiji sočasnega zdravljenja pri bolnikih z manično ali mešano epizodo, stabiliziranih z olanzapinom skupaj s stabilizatorjem razpoloženja (litij ali valproat), dolgotrajno sočasno zdravljenje z olanzapinom skupaj z litijem ali valproatom ni bilo statistično značilno bolj ugodno kot zdravljenje samo z litijem ali samo valproatom pri odlogu ponovnega pojava bipolarne motnje, določene po sindromnih (diagnostičnih) merilih.
In an 18-month bone efficacy study in aged ovariectomized cynomolgus monkeys, bazedoxifene, administered orally to monkeys at dosages of 0, 0.2, 0.5, 1, 5, or 25 mg/kg/day, resulted in exposures, based on surface area (mg/m2) of approximately 0.2 to 24 times the clinical dose of 20 mg.
V 18-mesečni študiji učinkovitosti za kosti pri starih ovariektomiranih opicah cinomolgus je bazedoksifen, ki so ga dajali opicam peroralno v odmerkih 0, 0,2, 0,5, 1, 5 ali 25 mg/kg/dan, povzročil izpostavljenosti, izražene na telesno površino (mg/m2), ki so se za 0,2- do 24-krat razlikovale od tiste pri kliničnem odmerku 20 mg.
In an 18-month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.
V 18-mesečni študiji sočasnega zdravljenja pri bolnikih z manično ali mešano epizodo, stabiliziranih z olanzapinom skupaj s stabilizatorjem razpoloženja (litij ali valproat), dolgotrajno sočasno zdravljenje z olanzapinom skupaj z litijem ali valproatom ni bilo statistično značilno bolj ugodno kot zdravljenje samo z litijem ali samo z valproatom pri odlogu ponovnega pojava bipolarne motnje, določene po sindromnih (diagnostičnih) merilih.
In an active controlled study of 78 weeks duration, dulaglutide was compared to insulin glargine, both on a background of metformin and a sulphonylurea.
Varnost in učinkovitost dulaglutida kot dodatka sulfonilsečnini so preučevali v študiji, nadzorovani s placebom, ki je trajala 24 tednov.
In an active-controlled clinical study (MI-CP111), an increased rate of hospitalisations (for any cause) through 180 days after final vaccination dose was observed in infants and toddlers 6-11 months of age (6.1% Fluenz versus 2.6% injectable influenza vaccine).
V aktivni kontrolirani klinični študiji (MI-CP111) so opazili povečano stopnjo hospitalizacij (zaradi vseh razlogov) v obdobju 180 dni po končnem odmerku vakcinacije pri dojenčkih in malčkih starih od 6 – 11 mesecev (6,1 % cepivo Fluenz v primerjavi z 2,6 % cepivo proti gripi, ki se injicira).
In an active-controlled clinical study in patients receiving HEC, safety was evaluated for 1,143 patients receiving the 1-day regimen of IVEMEND 150 mg compared to 1,169 patients receiving the 3-day regimen of aprepitant.
V z zdravilno učinkovino nadzorovani klinični študiji pri bolnikih, ki so prejemali zelo emetogeno kemoterapijo, so varnost ovrednotili pri 1.143 bolnikih, ki so prejeli 1-dnevni režim zdravljenja z zdravilom IVEMEND 150 mg, in pri 1.169 bolnikih, ki so prejeli 3-dnevni režim zdravljenja z aprepitantom.
In an active-controlled study, Lyxumia once daily showed an HbA1c reduction of -0.79% compared to -0.96% with exenatide twice daily at the end of the main 24-week treatment period with a mean treatment difference of 0.17% (95% CI: 0.033, 0.297) and a similar percentage of patients achieved an HbA1c less than 7% in the lixisenatide group (48.5%) and in the exenatide group (49.8%).
V študiji, kontrolirani z zdravilno učinkovino, je zdravilo Lyxumia enkrat na dan na koncu glavnega 24-tedenskega obdobja zdravljenja doseglo neinferiorno znižanje HbA1c v primerjavi z eksenatidom dvakrat na dan (Lyxumia -0,79 %, eksenatid –0,96 %); HbA1c manj kot 7 % je dosegel podoben delež bolnikov v skupini z zdravilom Lyxumia (48,5 %) kot v skupini z eksenatidom (49,8 %).
In an additional active-controlled clinical study in 1,169 patients receiving aprepitant and HEC, the adverse reactions profile was generally similar to that seen in the other HEC studies with aprepitant.
V dodatni z zdravilno učinkovino nadzorovani klinični študiji pri 1.169 bolnikih, ki so prejemali aprepitant in zelo emetogeno kemoterapijo, je bil profil neželenih učinkov na splošno podoben tistemu v drugih HEC študijah z aprepitantom.
In an additional four subjects administered 10.5 mg 14C-saquinavir intravenously, 81 % and 3 % of the intravenously administered radioactivity was recovered in faeces and urine, respectively, within 4 days of dosing.
Dodatno so štirim osebam dali 10,5 mg 14C-sakvinavirja intravensko, v blatu oziroma urinu so v 4 dneh po odmerjanju zaznali 81 % oziroma 3 % intravensko danega radioaktivno označenega.
In an additional study Mekinist did not show any benefit when given to patients who did not respond to previous treatment with another medicine called a BRAF inhibitor.
V dodatni študiji zdravila Mekinist, v kateri so ga dajali bolnikom, ki se niso odzvali na predhodno zdravljenje z drugim zdravilom, imenovanim zaviralec BRAF, niso opazili nobenih koristi.
In an analysis of PFS, PFS2, OS using a cut off of April 2013 where the median follow up time for all surviving subjects was 62.4 months, the results of the study are presented in Table 6:
V analizi PFS, PFS2, OS, kjer je bil datum zaključka zbiranja podatkov april 2013 in kjer je bila mediana časa spremljanja za vse preživele osebe 62,4 meseca, so rezultati študije predstavljeni v preglednici 6:
In an analysis of treatment-failure subjects in study GS-US-216-0114 through week 144, evaluable genotypic data from paired baseline and treatment-failure isolates were available for all 21 virologic failures in the cobicistat group.
V analizi bolnikov, pri katerih je bilo zdravljenje v študiji GS-US-216-0114 do konca 144. tedna neuspešno, so bili v skupini, zdravljeni s kobicistatom, pari genotipskih podatkov izolatov ob začetku zdravljenja in izolatov neuspešnega zdravljenja, ki jih je bilo mogoče oceniti, na voljo za vseh
In an animal model of infection, the antibacterial activity of tedizolid phosphate was reduced in the absence of granulocytes.
Pri živalskem modelu okužbe se je protibakterijsko delovanje tedizolid fosfata v odsotnosti granulocitov zmanjšalo.
In an animal study, no impairment of fertility was demonstrated in male and female rats (see section 5.3).
Študije na živalih niso pokazale zmanjšane plodnosti pri podganjih samcih in samicah (glejte poglavje 5.3).
In an early uncontrolled study without dexamethasone prophylaxis, single doses up to 125 mg were administered.
V začetni, nekontrolirani študiji brez profilakse z deksametazonom, so uporabili enojne odmerke do 125 mg.
In an embryo-foetal development study in the rat, increased incidences of dilated ureters, malformed sternebrae, and unossified forepaw phalanges were noticed at exposures of about 12 (valsartan) and 10 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine.
V študiji embriofetalnega razvoja pri podganah so pri izpostavljenosti, ki je bila za valsartan okrog 12- krat in za amlodipin okrog 10-krat večja kot ob kliničnih odmerkih 160 mg valsartana in 10 mg amlodipina, ugotovili večjo incidenco razširjenih ureterjev, malformirane sternebre in nezakostenele falange sprednjih tac.
In an embryofoetal development study in cynomolgus monkeys, secukinumab showed no maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis and late gestation.
V študiji razvoja zarodka in plodu pri opicah cinomolgus sekukinumab ni kazal potenciala za toksično delovanje na mater ali zarodek in za teratogenost, ko so ga odmerjali v času organogeneze in v pozni nosečnosti.
In an embryofoetal development study in marmosets canakinumab showed no maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis.
V študiji toksičnosti za razvoj zarodka oziroma ploda na marmozetkah, ki so jim kanakinumab dajali celotno obdobje organogeneze, se je pokazalo, da kanakinumab ne vpliva toksično niti na samice niti na zarodek in da ni teratogen.
In an EU field study involving 561 dogs with flea and/or tick infestations the effects of Bravecto tablets were compared with those of another product, fipronil, that kills fleas and ticks, applied as a spot-on solution to the skin of the dogs.
V terenski študiji, ki so jo opravili v EU in v katero so vključili 561 psov z bolhami in/ali klopi, so učinke zdravila Bravecto v obliki tablet primerjali z učinki drugega zdravila za ubijanje bolh in klopov, fipronila, ki se v obliki raztopine za kožni nanos nanese na kožo psov.
In an exploratory analysis, increasing age, especially aged 65 years and older, appeared to be associated with increased rates of neurological adverse events.
Eksploratorna analiza kaže, da bi lahko bila višja starost, še posebej nad 65 let, povezana z večjim deležem nevroloških neželenih dogodkov.
In an exploratory clinical study evaluating the use of infliximab in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies were reported in infliximab- treated patients compared with control patients.
V poskusnem kliničnem preskušanju za ovrednotenje uporabe infliksimaba pri bolnikih z zmerno do hudo kronično obstruktivno pljučno boleznijo (KOPB) so poročali o večjem številu malignomov pri bolnikih, zdravljenih z infliksimabom, kot pri tistih iz kontrolne skupine.
In an exploratory clinical study involving patients with moderate to severe COPD who were either current smokers or ex-smokers, 157 adult patients were treated with infliximab at doses similar to those used in rheumatoid arthritis and Crohn’s disease.
V poskusnem kliničnem preskušanju pri bolnikih z zmerno do hudo KOPB, ki so bili bodisi aktivni kadilci ali bivši kadilci, je bilo 157 odraslih bolnikov zdravljenih z infliksimabom v odmerkih, podobnih tistim, ki se uporabljajo pri revmatoidnem artritisu in pri Crohnovi bolezni.
In an exploratory clinical study involving patients with moderate to severe COPD who were either current smokers or ex-smokers, 157 adult patients were treated with infliximab at doses similar to those used in rheumatoid arthritis and Crohn’s disease.
V poskusnem kliničnem preskušanju pri bolnikih z zmerno do hudo KOPB, ki so bili bodisi aktivni kadilci ali bivši kadilci, je bilo 157 odraslih bolnikov zdravljenih z zdravilom infliksimab v odmerkih, podobnih tistim, ki se uporabljajo pri revmatoidnem artritisu in pri Crohnovi bolezni.
In an exploratory clinical study involving patients with moderate to severe COPD who were either current smokers or ex-smokers, 157 adult patients were treated with Remicade at doses similar to those used in rheumatoid arthritis and Crohn’s disease.
V poskusnem kliničnem preskušanju pri bolnikih z zmerno do hudo KOPB, ki so bili bodisi aktivni kadilci ali bivši kadilci, je bilo 157 odraslih bolnikov zdravljenih z zdravilom Remicade v odmerkih, podobnih tistim, ki se uporabljajo pri revmatoidnem artritisu in pri Crohnovi bolezni.
In an exploratory clinical trial evaluating the use of another anti-TNF agent, infliximab, in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung or head and neck, were reported in infliximab-treated patients compared with control patients.
V eksploratornem kliničnem preskušanju za oceno uporabe drugega zaviralca TNF, infliksimaba, pri bolnikih z zmerno do hudo kronično obstruktivno pljučno boleznijo (KOPB) so poročali o večjem številu malignomov, večinoma v predelu pljuč ter glave in vratu pri bolnikih, ki so bili zdravljeni z infliksimabom, v primerjavi s tistimi iz kontrolne skupine.
In an exploratory clinical trial evaluating the use of Simponi in patients with severe persistent asthma, more malignancies were reported in patients treated with Simponi compared with control patients (see section 4.8).
V eksploratornem kliničnem preskušanju za oceno uporabe zdravila Simponi pri bolnikih s hudo trdovratno astmo so pri bolnikih, zdravljenih z zdravilom Simponi, poročali o večjem številu malignomov kot pri tistih iz kontrolne skupine (glejte poglavje 4.8).
In an exploratory retrospective analysis of data from 13 completed randomised trials in patients with various tumour types, 3 patients out of 91 (3.3%) with brain metastases experienced CNS bleeding (all Grade 4) when treated with bevacizumab, compared to 1 case (Grade 5) out of 96 patients (1%) that were not exposed to bevacizumab.
V eksplorativni retrospektivni analizi podatkov iz 13 zaključenih randomiziranih kliničnih preskušanj pri bolnikih z različnimi vrstami tumorjev so 3 bolniki od 91 (3,3 %), ki so imeli zasevke v možganih, imeli krvavitev v osrednjem živčevju (vsi stopnje 4) pri zdravljenju z bevacizumabom, v primerjavi z 1 primerom (stopnja 5) od 96 bolnikov (1 %), ki niso bili izpostavljeni bevacizumabu.
In an extended treatment study in Asian patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at the end of the 5 year treatment period was 48 % (28/58) and 47 % (15/32), respectively.
V študiji podaljšanega zdravljenja pri bolnikih v Aziji (NUCB3018) je bil ob zaključku 5-letnega zdravljenja odstotek serokonverzije HBeAg 48 % (28/58), odstotek normalizacije ALT pa 47 % (15/32).
In an extended treatment study in Asian patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at the end of the 5 year treatment period was 48 % (28/58) and 47 % (15/32), respectively.
V študiji podaljšanega zdravljenja pri bolnikih v Aziji (NUCB3018) je bil ob zaključku petletnega zdravljenja delež serokonverzije HBeAg 48 % (28/58), delež normalizacije ALT pa 47 % (15/32).
In an extension of this study, 13 PID patients (aged 3-65 years) participated in a PK sub-study.
V razširitvi te študije je bila pri trinajstih bolnikih s PID (starih od 3–65 let) opravljena dodatna farmakokinetična podštudija.
In an HCV subtype 1b replicon assay, the telaprevir IC50 value against wild-type HCV was 0.354 µM similar to a subtype 1a infectious virus assay IC50 of 0.28 µM.
Pri testu podtipa 1b replikona HCV je IC50 za telaprevir v primerjavi z divjim tipom virusa HCV znašala 0,354 µM, podobno kot pri določanju IC50 za podtip 1a infekcioznega virusa, ki je znašala 0,28 µM.
In an ICGG Gaucher Registry analysis of a large cohort of patients (n=528) with Gaucher disease type 1, a time- and dose-dependent effect for Cerezyme was observed for haematological and visceral parameters (platelet count, haemoglobin concentration, spleen and liver volume) within the dose range of 15, 30 and 60 U/kg body weight once every 2 weeks.
Pri analizi Gaucherjevega registra Mednarodne sodelovalne skupine za Gaucherjevo bolezen (International Collaborative Gaucher Group (ICGG) Gaucher Registry) velike skupine bolnikov (n=528) z Gaucherjevo boleznijo tipa 1, so pri hematoloških in visceralnih parametrih (število trombocitov, koncentracija hemoglobina, volumen vranice in jeter) v razponu odmerkov 15, 30 in 60 enot/kg telesne mase enkrat na vsaka 2 tedna opazili učinek zdravila Cerezyme, odvisen od velikosti in časa odmerjanja,.
In an imaging sub-study including 153 patients, signs of inflammation were assessed by MRI at week 12 and expressed as change from baseline in SPARCC (Spondyloarthritis Research Consortium of Canada) score for sacroiliac joints and ASspiMRI-a score in the Berlin modifications for the spine.
V podštudiji, ki je vključevala 153 bolnikov, so v 12. tednu z magnetno resonanco ocenjevali znake vnetja, izraženo kot sprememba od izhodišča po lestvici SPARCC (Kanadski raziskovalni konzorcij za spondiloartritis) za sakroiliakalne sklepe in po lestvici ASspiMRI-a iz Berlinske modifikacijske metode za hrbtenico.
In an in vitro metabolism study, following the incubation of [14C]-dexamethasone with human cornea, iris-ciliary body, choroid, retina, vitreous humour, and sclera tissues for 18 hours, no metabolites were observed.
V študiji presnove in vitro po 18-urni inkubaciji 14C-deksametazona s človeško roženico, šarenico- ciliarnikom, žilnico, mrežnico, steklovino in tkivi beločnice niso opazili nobenih presnovkov.
In an in vitro study, temsirolimus inhibited the transport of P-glycoprotein (P-gp) substrates with an IC50 value of 2 µM. In vivo, the effect of P-gp inhibition has not been investigated in a clinical drug- drug interaction study, however, recent preliminary data from a Phase 1 study of combined lenalidomide (dose of 25 mg) and temsirolimus (dose of 20 mg) seem to support the in vitro findings and suggest an increased risk of adverse events.
V študiji in vitro je temsirolimus zaviral transport substratov P-glikoproteina (P-gp) z vrednostjo IC50 2 µM. In vivo učinka zaviranja P-gp v kliničnih študijah medsebojnega delovanja niso raziskali, vendar pa nedavni preliminarni podatki iz študije 1. faze kažejo, da uporaba kombinacije lenalidomida (odmerek 25 mg) in temsirolimusa (odmerek 20 mg) podpira rezultate in vitro in kaže na povečano tveganje za pojav neželenih učinkov.
In an in vitro whole blood assay in dogs, robenacoxib was approximately 140 fold selective for COX-2 (IC50 0.04 μM) as compared to COX-1 (IC50 7.9 μM).
Raziskave celokupne krvi pri psih in vitro so pokazale, da je selektivnost robenakoksiba približno 140- krat večja za COX-2 (IC50 0,04 μM) kot za COX-1 (IC50 7,9 μM).
In an in vivo drug-drug interaction study performed with ketoconazole, there was no clinically relevant effect on the levels of safinamide.
In vivo študija interakcij med zdravili, ki so jo opravili s ketokonazolom, ni pokazala klinično pomembnega učinka na ravni safinamida.
In an independent published study,
v neodvisni objavljeni študiji,
In an independent published study,
v neodvisni, objavljeni študiji,
In an independent published study, Alfentanil AUC0-∞  6- fold.
v neodvisni objavljeni študiji, alfentanil AUC  6-krat
In an independent published study, Fentanyl AUC0-  1.34-fold
v neodvisni objavljeni študiji, fentanil AUC0-  1,34-krat
In an independent published study, Voriconazole AUC0-∞ ↓ 59%
v neodvisni, objavljeni študiji, vorikonazol AUC0-∞ ↓ 59
In an inflammation model in cats, robenacoxib injection had analgesic, anti-inflammatory and anti-pyretic effects and a rapid onset of action (0.5 h).
Pri vnetnem modelu pri mačkah je injiciranje robenakoksiba učinkovalo hitro (0,5 h) protibolečinsko, protivnetno in antipiretično.
In an infusion bag: up to 8 hours not above 25°C.
V infuzijski vrečki: do 8 ur pri temperaturi do 25 oC
In an infusion bag: up to 8 hours not above 25°C.
V infuzijski vrečki: do 8 ur pri temperaturi do 25 oC.
In an insulin infusion pump.
V infuzijski črpalki za insulin.